Hercules

Hercules Capital Prices Upsized Public Offering of $350.0 Million 3.375% Notes due 2027

Retrieved on: 
Friday, January 14, 2022 - 10:33pm

Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), today announced that it has priced an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the Notes).

Key Points: 
  • Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), today announced that it has priced an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the Notes).
  • The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on January 20, 2022.
  • Goldman Sachs & Co. LLC, RBC Capital Markets, LLC, and SMBC Nikko Securities America, Inc. are acting as joint book-running managers of this offering.
  • In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY).

TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million

Retrieved on: 
Tuesday, January 4, 2022 - 12:30pm

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $200 million, with $70 million funded at closing.

Key Points: 
  • NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $200 million, with $70 million funded at closing.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, We are pleased to announce the expansion of our term loan facility with Hercules Capital and the immediate draw of $70 million.
  • Michael Dutra, Managing Director at Hercules Capital shared, Hercules is excited to continue and expand our partnership with TG Therapeutics as they advance their pipeline and work to bring their treatments to patients.
  • Under the terms of the amendment, the size of the term loan facility was increased to $200 million, with $70 million available and drawn at closing on December 30, 2021.

Citycon continues to execute on the 300,000 sqm residential potential across the Nordics

Retrieved on: 
Wednesday, December 22, 2021 - 10:41am

Construction of this unique residential project will complement and enhance Citycon's existing necessity-based retail asset, Herkules Senter, started this fall and is progressing on schedule.

Key Points: 
  • Construction of this unique residential project will complement and enhance Citycon's existing necessity-based retail asset, Herkules Senter, started this fall and is progressing on schedule.
  • Over the past ten years, the joint venture has built 160 residential units in the Herkules area and is excited to add to this growing and vital community.
  • Citycon has created a significant residential pipeline of 20 projects in the Nordics.
  • The residential projects are distributed across the operating countries with multiple locations well distributed across Norway, Sweden, Finland and Estonia.

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

Retrieved on: 
Wednesday, December 1, 2021 - 12:00pm

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer.
  • We are excited to welcome Jeb to the team during an important phase of AVEOs evolution as an integrated clinical development and commercial organization, said Michael Bailey, president and chief executive officer of AVEO.
  • I am excited to be joining AVEO during this dynamic growth phase for the company, said Mr. Ledell.
  • Prior to Enzyvant, Mr. Ledell served as the chief operating officer at Compass Therapeutics and Horizon Discovery Group.

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

Retrieved on: 
Monday, November 29, 2021 - 2:00pm

This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.

Key Points: 
  • This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.
  • To date there have been 4 approvals and two applications pending review, said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Hercules Capital Surpasses $2.0 Billion in Annual Gross Debt and Equity Commitments for First Time in History

Retrieved on: 
Monday, November 29, 2021 - 11:00am

Having just achieved record quarterly commitments in Q3 2021, our industry-leading venture and growth stage lending platform continues at its unprecedented pace and has now passed the $2 billion mark in annual gross debt and equity commitments for the first time in our history, said Scott Bluestein, chief executive officer and chief investment officer of Hercules Capital.

Key Points: 
  • Having just achieved record quarterly commitments in Q3 2021, our industry-leading venture and growth stage lending platform continues at its unprecedented pace and has now passed the $2 billion mark in annual gross debt and equity commitments for the first time in our history, said Scott Bluestein, chief executive officer and chief investment officer of Hercules Capital.
  • Since inception (December 2003), Hercules has committed more than $13 billion to over 540 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.
  • Hercules Capital, through its wholly owned subsidiary, Hercules Adviser LLC (Hercules Adviser), also maintains an asset management business through which it manages investments for external parties (Adviser Funds).
  • Hercules Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.

BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing

Retrieved on: 
Thursday, November 18, 2021 - 12:30pm

PALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to $750.0 million in financing.

Key Points: 
  • As structured, this financing is expected to fully fund BridgeBios portfolio of more than 30 drug development and discovery programs into 2024, independent of near-term milestone readouts.
  • This financing announcement follows BridgeBios repurchase of approximately $150.0 million in its own common stock under its 2021 Share Repurchase Program, completing about $385.6 million of equity and capped call purchases in the aggregate since its initial public offering in 2019.
  • In addition, todays financing replaces the Companys $100.0 million debt facility with Hercules.
  • Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Hercules Capital Announces Upcoming Events for the Financial Community

Retrieved on: 
Tuesday, November 9, 2021 - 9:10pm

Since inception (December 2003), Hercules has committed more than $12.8 billion to over 540 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.

Key Points: 
  • Since inception (December 2003), Hercules has committed more than $12.8 billion to over 540 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.
  • Hercules Capital, through its wholly owned subsidiary, Hercules Adviser LLC (Hercules Adviser), also maintains an asset management business through which it manages investments for external parties (Adviser Funds).
  • The information disclosed in this press release is made as of the date hereof and reflects Hercules most current assessment of its historical financial performance.
  • The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021

Retrieved on: 
Tuesday, October 26, 2021 - 12:01pm

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Hercules Capital Announces Supplemental Cash Distribution of $0.07 per Share for the Third Quarter of 2021

Retrieved on: 
Tuesday, October 26, 2021 - 11:03am

This supplemental cash distribution will be paid out of Hercules Capitals undistributed taxable income (taxable income in excess of distributions paid) as of September 30, 2021.

Key Points: 
  • This supplemental cash distribution will be paid out of Hercules Capitals undistributed taxable income (taxable income in excess of distributions paid) as of September 30, 2021.
  • The following shows the key dates of the supplemental distribution payment:
    This supplemental cash distribution is in addition to the previously announced regular quarterly cash distribution that Hercules declared for the third quarter of 2021 of $0.33 per share.
  • The percentage of QII for distributions declared for the third quarter ended September 30, 2021 on Hercules Capital, Inc.s common stock is 88.6%.
  • Hercules Capital, through its wholly owned subsidiary, Hercules Adviser LLC (Hercules Adviser), also maintains an asset management business through which it manages investments for external parties.